Struggling Amarin jousts with activist investor Sarissa as board vote nears

With sales of Vascepa tanking in the U.S. and Amarin working to get the heart-helping drug to the market in Europe, activist investor Sarissa Capital Management is attempting to oust Chairman Per Wold-Olsen and muscle its way onto the company’s board of directors.